Table 1 Patient background and clinical course in MS and NMOSD.
MS (n = 62) | NMOSD (n = 33) | p-value | |
|---|---|---|---|
Male:Female | 12:50 | 3:30 | 0.25 |
Onset age (mean ± SD) | 29.9 ± 8.6 | 48.5 ± 13.8 | < 0.0001 |
Total EDSS follow-up period (person-year) | 337 | 229 | – |
EDSS follow-up years per capita (median, IQR) | 6 (3–7) | 7 (5–9) | 0.0460 |
Cross-sectional EDSS | |||
EDSS at 5 years from onset (median, IQR) | 1.5 (1.0–2.0; n = 53) | 3.0 (2.0–5.0; n = 31) | < 0.0001 |
EDSS at 10 years from onset (median, IQR) | 1.5 (1.0–2.0; n = 20) | 4.5 (3.0–6.5; n = 18) | 0.0002 |
EDSS annual deterioration (person-year) | |||
Total | 28/337 (8.3%) | 20/229 (8.7%) | 0.86 |
(With relapse) | 11 (3.3%) | 13 (5.7%) | 0.16 |
(Without relapse) | 17 (5.0%) | 7 (3.1%) | 0.29 |
EDSS annual improvement (person-year) | |||
Total | 32/337 (9.5%) | 4/229 (1.7%) | 0.0001 |
(With relapses) | 5 (1.5%) | 2 (0.9%) | 0.71 |
(Without relapses) | 27 (8.0%) | 2 (0.9%) | < 0.0001 |
EDSS annually unchanged (person-year) | |||
Total | 277/337 (82.2%) | 205/229 (89.5%) | 0.0161 |
(With relapses) | 22 (6.5%) | 8 (3.5%) | 0.13 |
(Without relapses) | 255 (75.7%) | 197 (86.0%) | 0.0026 |
